Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more
Citius Oncology, Inc. (CTOR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.126x
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.126x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.35 Million) by net assets ($58.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Citius Oncology, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Legacy Minerals Holdings Ltd
AU:LGM
|
-0.075x |
|
Otto Energy Limited
PINK:OTTEF
|
0.100x |
|
Belysse Group N.V.
BR:BELYS
|
0.223x |
|
Victory Square Technologies Inc
OTCQB:VSQTF
|
-0.066x |
|
Viva Gold Corp
OTCQB:VAUCF
|
-0.197x |
|
Ecocera Optronics Co., Ltd.
TWO:6597
|
-0.003x |
|
FACILITIES BY ADF LS-01
F:ZC8
|
N/A |
|
Global Oil & Gas Limited
PINK:BAKPF
|
-0.099x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |